Clinical ramifications of the MHC family Fc receptor FcRn

Journal of Clinical Immunology

Volumn 30, Issue 6, 2010, Pages 790-797

  Roopenian, Derry C ^a   Sun, Victor Z ^a  

^a JACKSON LABORATORY   (United States)

Author keywords

2 microglobulin; Albumin; Fcgrt; FcRn; Neonatal Fc receptor; Therapeutic antibodies

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BEVACIZUMAB; CETUXIMAB; ETANERCEPT; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MYOTONIC DYSTROPHY PROTEIN KINASE; OKT 3;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; GENETIC VARIABILITY; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN STRUCTURE; IMMUNOMODULATION; IMMUNOTHERAPY; LOSS OF FUNCTION MUTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOGENIC DISORDER; NEOPLASM; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ALBUMINS; ANIMALS; AUTOIMMUNITY; BLOOD CIRCULATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; INTESTINES; MAJOR HISTOCOMPATIBILITY COMPLEX; PLACENTA; PLACENTAL CIRCULATION; PREGNANCY; PROTEIN ENGINEERING; RECEPTORS, FC;

EID: 78651301749     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9458-6     Document Type: Article

References (71)

1. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1-110.
2. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest. 1999;104:903-11.
3. Masuda A, Yoshida M, Shiomi H, Morita Y, Kutsumi H, Inokuchi H, et al. Role of Fc receptors as a therapeutic target. Inflamm Allergy Drug Targets. 2009;8:80-6.
4. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-25.
5. Ward ES, Ober RJ. Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol. 2009;103:77-115.
6. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol. 1996;12:181-220.
7. Simister NE, Ahouse JC, Res Immunol. The structure and evolution of FcRn. Res Immunol. 1996;147:333-7. discussion 53.
8. Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature. 1994;372:336-43.
9. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372:379-83.
10. West Jr AP, Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor (,). Biochemistry. 2000;39:9698-708.
11. Martin WL, West Jr AP, Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001;7:867-77.
12. Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure. 1998;6:63-73.
13. McCarthy KM, Yoong Y, Simister NE. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. J Cell Sci. 2000;113(Pt 7):1277-85.
14. Wu Z, Simister NE. Tryptophan-and dileucine-based endocytosis signals in the neonatal Fc receptor. J Biol Chem. 2001;276:5240-7.
15. Newton EE, Wu Z, Simister NE. Characterization of basolateraltargeting signals in the neonatal Fc receptor. J Cell Sci. 2005;118:2461-9.
16. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352-4.
17. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93:5512-6.
18. Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the singlemolecule level. Proc Natl Acad Sci U S A. 2004;101:11076-81.
19. Ward ES, Martinez C, Vaccaro C, Zhou J, Tang Q, Ober RJ. From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell. 2005;16:2028-38.
20. Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic. 2009;10:600-14.
21. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complexrelated Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197:315-22.
22. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 2006;27:343-8.
23. Kim J, Bronson CL, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol. 2006;290: G352-60.
24. Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2006;122(2):146-55.
25. Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet. 2009;24:318-32.
26. Peters Jr T. Serum albumin. Adv Protein Chem. 1985;37:161-245.
27. Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry. 2006;45:4983-90.
28. Andersen JT, Dee Qian J, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol. 2006;36:3044-51.
29. Ramalingam TS, Detmer SA, Martin WL, Bjorkman PJ. IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution. EMBO J. 2002;21:590-601.
30. Tzaban S, Massol RH, Yen E, Hamman W, Frank SR, Lapierre LA, et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol. 2009;185:673-84.
31. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity. 2004;20:769-83.
32. Yoshida M, Masuda A, Kuo TT, Kobayashi K, Claypool SM, Takagawa T, et al. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin Immunopathol. 2006;28:397-403. (Pubitemid 44900578)
33. Kobayashi K, Qiao SW, Yoshida M, Baker K, Lencer WI, Blumberg RS. An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology. 2009;137:1746-56. e1.
34. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol. 2001;166:3266-76.
35. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol. 2007;179:4580-8.
36. Sarav M, Wang Y, Hack BK, Chang A, Jensen M, Bao L, et al. Renal FcRn reclaims albumin but facilitates elimination of IgG. J Am Soc Nephrol. 2009;20:1941-52.
37. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol. 2008;20:460-70.
38. Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009;20:685-91.
39. Humphrey JH, Fahey JL. The metabolism of normal plasma proteins and gamma-myeloma protein in mice bearing plasma-cell tumors. J Clin Invest. 1961;40:1696-705.
40. Jin F, Balthasar JP. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol. 2005;66:403-10.
41. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13:1551-9.
42. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol. 2000;18:739-66.
43. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591-604.
44. Zhou J, Johnson JE, Ghetie V, Ober RJ, Ward ES. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol. 2003;332:901-13.
45. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23:1283-8.
46. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol. 1997;15:637-40.
47. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004;279:6213-6.
48. Kamei DT, Lao BJ, Ricci MS, Deshpande R, Xu H, Tidor B, et al. Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol Bioeng. 2005;92:748-60.
49. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514-24.
50. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum halflife. J Immunol. 2006;176:346-56.
51. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18:1759-69.
52. Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol. 2009;46:1750-5.
53. Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A. 2006;103:18709-14.
54. Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol. 2010;602:93-104.
55. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28:157-9.
56. Wani MA, Haynes LD, Kim J, Bronson CL, Chaudhury C, Mohanty S, et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A. 2006;103:5084-9.
57. Wochner RD, Drews G, Strober W, Waldmann TA. Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism. J Clin Invest. 1966;45:321-9.
58. Zinneman HH, Rotstein J. A study of gamma globulins in dystrophia myotonica. J Lab Clin Med. 1956;47:907-16.
59. Roberts DF, Bradley WG. Immunoglobulin levels in dystrophia myotonica. J Med Genet. 1977;14:16-9.
60. Pan-Hammarstrom Q, Wen S, Ghanaat-Pour H, Solders G, Forsberg H, Hammarstrom L. Lack of correlation between the reduction of serum immunoglobulin concentration and the CTG repeat expansion in patients with type 1 dystrophia [correction of Dystrofia] myotonica. J Neuroimmunol. 2003;144:100-4.
61. Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans. 2009;37:1281-6.
62. Klesert TR, Cho DH, Clark JI, Maylie J, Adelman J, Snider L, et al. Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy. Nat Genet. 2000;25:105-9.
63. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001;29:40-7.
64. Junghans RP, Ebralidze A, Tiwari B. Does (CUG) n repeat in DMPK mRNA 'paint' chromosome 19 to suppress distant genes to create the diverse phenotype of myotonic dystrophy?: a new hypothesis of long-range cis autosomal inactivation. Neurogenetics. 2001;3:59-67.
65. Junghans RP. Dystrophia myotonia: why focus on foci? Eur J Hum Genet. 2009;17:543-53.
66. Christianson GJ, Brooks W, Vekasi S, Manolfi EA, Niles J, Roopenian SL, et al. Beta 2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol. 1997;159:4781-92.
67. Mayer B, Doleschall M, Bender B, Bartyik J, Bosze Z, Frenyo LV, et al. Expression of the neonatal Fc receptor (FcRn) in the bovine mammary gland. J Dairy Res. 2005;72:107-12.
68. Zhang R, Zhao Z, Zhao Y, Kacskovics I, Eijk M, Groot N, et al. Association of FcRn heavy chain encoding gene (FCGRT) polymorphisms with IgG content in bovine colostrum. Anim Biotechnol. 2009;20:242-6.
69. Sachs UJ, Socher I, Braeunlich CG, Kroll H, Bein G, Santoso S. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology. 2006;119:83-9.
70. Zhou XJ, Yu L, Zhu L, Hou P, Lv JC, Yu F, et al. Association between polymorphisms in the FCGRT gene and lupus nephritis in Chinese patients. Clin Exp Rheumatol. 2009;27:609-14.
71. Freiberger T, Ravcukova B, Grodecka L, Kurecova B, Jarkovsky J, Bartonkova D, et al. No association of FCRN promoter VNTR polymorphism with the rate of maternal-fetal IgG transfer. J Reprod Immunol. 2010;85:193-7.